Associate Scientist, Inflammation and Chronic Disease
Ottawa Hospital Research Institute

Hematologist, Department of Medicine
The Ottawa Hospital

Assistant Professor, Department of Medicine
University of Ottawa

Anticoagulant safety; Venous thromboembolism; Health disparities; Thrombotic conditions in racialized populations.

Dr. Yan Xu is a clinician-scientist and Canada Research Chair (Tier 2) in Thrombosis at the University of Ottawa and the Ottawa Hospital Research Institute. His expertise spans venous thromboembolism (VTE), anticoagulation, bleeding risk prediction, and health equity in thrombosis care. He leads an interdisciplinary research program focused on improving diagnosis, treatment, and outcomes of VTE, particularly among racialized and linguistically diverse populations who experience systemic barriers to high-quality care.

Dr. Xu has a track record of impactful scholarship, with first- or senior-author publications in leading journals including JAMA, BMJ, Chest, Blood Advances, and Journal of Thrombosis and Haemostasis. He has secured over $600,000 in competitive funding as Principal Investigator or Co-Principal Investigator, including support from CIHR, Canada Foundation for Innovation, the Royal College of Physicians and Surgeons of Canada, and international societies. His program integrates epidemiology, administrative databases, systematic reviews, and patient-partnered methods to inform precision risk prediction and equitable care delivery.

A committed mentor, Dr. Xu supervises trainees across graduate, medical, and undergraduate levels, many of whom have achieved awards and national presentations. He also contributes to national and international leadership roles, including serving on the CHEST VTE Prevention Guideline Panel.

1. Xu Y, Cole K, Collins E, Moledina A, Mallity C, Carrier M. Anticoagulation for the prevention of arterial thrombosis in ambulatory cancer patients: Systematic review and meta-Analysis. Journal of the American College of Cardiology CardioOncology. E-published Jun 27, 2023.

2. Xu Y, Gomes T, Wells PS, Pequeno P, Johnson AP, Sholzberg M. Evaluation of major bleeding definitions for oral anticoagulant-associated bleeding: a population-based cohort study. Thrombosis Research. 2022;213:57-64.

3. Xu Y, Siegal DM, Anand S. Ethnoracial variations in venous thrombosis: implications for management and call to action. Journal of Thrombosis and Haemostasis. 2021;19(1):30-40.

4. Sholzberg M, Xu Y. Coagulation test interpretation in direct oral anticoagulant associated bleeding. JAMA. 2018;320(14):1485-1486

5. Xu Y, Schulman S, Dowlatshahi D, Holbrook AM, Simpson CS, Shepherd LE, Wells PS, Giulivi A, Gomes T, Mamdani M, Khuu W, Frymire E, Johnson A. Direct oral anticoagulantor warfarin-related major bleeding: Characteristics, management and outcomes from a multicenter observational study. Chest. 2017;152(1):81-91.
 

Health equity; Health in disadvantaged peoples; Population health; Thrombosis / thromboembolism